MarketPulse

antisense oligonucleotide

3 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Dyne Therapeutics Launches Phase 3 Trial for Z-Basivarsen in Myotonic Dystrophy

Dyne Therapeutics initiates Phase 3 HARMONIA trial testing z-basivarsen in approximately 150 DM1 patients, aiming to convert accelerated approval to traditional FDA clearance.
DYNPhase 3 clinical trialFDA approval
GlobeNewswire Inc.GlobeNewswire Inc.··Aligos Therapeutics, Inc.

Aligos Therapeutics Cuts Losses 82% While Advancing Hepatitis B Pipeline

Aligos reports $24.2M net loss in 2025, down 82% YoY. Key hepatitis B study enrollment complete; cash runway extends to Q3 2026.
ALGSPhase 2 clinical trialfinancial results
GlobeNewswire Inc.GlobeNewswire Inc.··Custom Market Insights

ALS Therapeutics Market Poised to More Than Double by 2035

ALS therapeutics market to more than double by 2035, reaching $1.96 billion. Growth driven by genetic therapies, improved diagnostics, and disease awareness.
CYTKBIIBIONSAMLXrare diseasegene therapy